Please assess the completion status of the following clinical trial:

Trial Title: Repeated Amiodarone Dosing In Cardiac surgicaL Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be 18 years old or older~* Subject must be willing to give written informed consent~* Subject must undergo or scheduled for non-emergent cardiac surgery, including coronary artery bypass grafting (CABG), non-infectious valve repair or replacement, atrial or septal defect repair, thoracic aortic replacement surgery, or any combination of these procedures~Exclusion Criteria:~* Documented allergy to amiodarone or iodine~* History of atrial fibrillation or other heart conduction system abnormality~* History of cardiac maze, pulmonary vein isolation, or other procedure affecting the conduction system~* Scheduled cardiac maze, pulmonary vein isolation, or other procedure affecting the conduction system~* Low cardiac index or cardiogenic shock requiring pharmacologic or mechanical support~* History of pre-existing respiratory system disease requiring oxygen therapy prior to admission~* History of cirrhosis or other chronic liver diseases~* Pregnancy or breastfeeding mothers~* Prisoner status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional amiodarone dosing regimen (CDR) (Type: ACTIVE_COMPARATOR): Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
- Repeated amiodarone bolus dosing regimen (RBDR) (Type: ACTIVE_COMPARATOR): Initial amiodarone bolus of 150 mg IV over 10 minutes, then 1.0 mg/min IV amiodarone infusion for 6 hours, then a 0.5 mg/min IV amiodarone infusion for 18 hours, followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. In addition, patients in the RBDR will receive an additional 150 mg IV amiodarone bolus whenever the patient develops tachycardia (Heart Rate (HR) = 110 beats per minute) lasting more than 10 minutes. This bolus may be repeated up to a total of 5 times (6 total boluses) over the first 24 hours. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).